Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD007 + MGA012 in metastatic colorectal cancer
NCT03531632Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of MGD007 in colorectal cancer (metastatic) (mCRC), sponsored by MacroGenics. Started Jun 2018; status: completed.
02
Drugs
MGD007
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03531632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531632.